These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 24018545)

  • 1. A randomized, double-blind comparison of atomoxetine and placebo on response inhibition and interference control in children and adolescents with autism spectrum disorder and comorbid attention-deficit/hyperactivity disorder symptoms.
    van der Meer JM; Harfterkamp M; van de Loo-Neus G; Althaus M; de Ruiter SW; Donders AR; de Sonneville LM; Buitelaar JK; Hoekstra PJ; Rommelse NN
    J Clin Psychopharmacol; 2013 Dec; 33(6):824-7. PubMed ID: 24018545
    [No Abstract]   [Full Text] [Related]  

  • 2. A randomized double-blind study of atomoxetine versus placebo for attention-deficit/hyperactivity disorder symptoms in children with autism spectrum disorder.
    Harfterkamp M; van de Loo-Neus G; Minderaa RB; van der Gaag RJ; Escobar R; Schacht A; Pamulapati S; Buitelaar JK; Hoekstra PJ
    J Am Acad Child Adolesc Psychiatry; 2012 Jul; 51(7):733-41. PubMed ID: 22721596
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term treatment with atomoxetine for attention-deficit/hyperactivity disorder symptoms in children and adolescents with autism spectrum disorder: an open-label extension study.
    Harfterkamp M; Buitelaar JK; Minderaa RB; van de Loo-Neus G; van der Gaag RJ; Hoekstra PJ
    J Child Adolesc Psychopharmacol; 2013 Apr; 23(3):194-9. PubMed ID: 23578015
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Atomoxetine for the treatment of attention-deficit/hyperactivity disorder and oppositional defiant disorder.
    Bangs ME; Hazell P; Danckaerts M; Hoare P; Coghill DR; Wehmeier PM; Williams DW; Moore RJ; Levine L;
    Pediatrics; 2008 Feb; 121(2):e314-20. PubMed ID: 18245404
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Response to atomoxetine in boys with high-functioning autism spectrum disorders and attention deficit/hyperactivity disorder.
    Zeiner P; Gjevik E; Weidle B
    Acta Paediatr; 2011 Sep; 100(9):1258-61. PubMed ID: 21392103
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Atomoxetine hydrochloride in the treatment of children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: A placebo-controlled Italian study.
    Dell'Agnello G; Maschietto D; Bravaccio C; Calamoneri F; Masi G; Curatolo P; Besana D; Mancini F; Rossi A; Poole L; Escobar R; Zuddas A;
    Eur Neuropsychopharmacol; 2009 Nov; 19(11):822-34. PubMed ID: 19716683
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Open-label atomoxetine for attention-deficit/ hyperactivity disorder symptoms associated with high-functioning pervasive developmental disorders.
    Posey DJ; Wiegand RE; Wilkerson J; Maynard M; Stigler KA; McDougle CJ
    J Child Adolesc Psychopharmacol; 2006 Oct; 16(5):599-610. PubMed ID: 17069548
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Once-daily treatment with atomoxetine in adults with attention-deficit/hyperactivity disorder: a 24-week, randomized, double-blind, placebo-controlled trial.
    Young JL; Sarkis E; Qiao M; Wietecha L
    Clin Neuropharmacol; 2011; 34(2):51-60. PubMed ID: 21406998
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Atomoxetine for attention-deficit/hyperactivity disorder symptoms in children with pervasive developmental disorders: a pilot study.
    Troost PW; Steenhuis MP; Tuynman-Qua HG; Kalverdijk LJ; Buitelaar JK; Minderaa RB; Hoekstra PJ
    J Child Adolesc Psychopharmacol; 2006 Oct; 16(5):611-9. PubMed ID: 17069549
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized, double-blind study of continuation treatment for attention-deficit/hyperactivity disorder after 1 year.
    Buitelaar JK; Michelson D; Danckaerts M; Gillberg C; Spencer TJ; Zuddas A; Faries DE; Zhang S; Biederman J
    Biol Psychiatry; 2007 Mar; 61(5):694-9. PubMed ID: 16893523
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of parent and teacher reports of attention-deficit/hyperactivity disorder symptoms from two placebo-controlled studies of atomoxetine in children.
    Biederman J; Gao H; Rogers AK; Spencer TJ
    Biol Psychiatry; 2006 Nov; 60(10):1106-10. PubMed ID: 16806096
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Atomoxetine treatment outcomes in adolescents and young adults with attention-deficit/hyperactivity disorder: results from a post hoc, pooled analysis.
    Adler LA; Wilens T; Zhang S; Dittmann RW; D'Souza DN; Schuh L; Durell TM
    Clin Ther; 2012 Feb; 34(2):363-73. PubMed ID: 22285724
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of atomoxetine on executive function impairments in adults with ADHD.
    Brown TE; Holdnack J; Saylor K; Adler L; Spencer T; Williams DW; Padival AK; Schuh K; Trzepacz PT; Kelsey D
    J Atten Disord; 2011 Feb; 15(2):130-8. PubMed ID: 20026871
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Atomoxetine treatment of attention-deficit/hyperactivity disorder in young adults with assessment of functional outcomes: a randomized, double-blind, placebo-controlled clinical trial.
    Durell TM; Adler LA; Williams DW; Deldar A; McGough JJ; Glaser PE; Rubin RL; Pigott TA; Sarkis EH; Fox BK
    J Clin Psychopharmacol; 2013 Feb; 33(1):45-54. PubMed ID: 23277268
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Atomoxetine treatment in children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder.
    Newcorn JH; Spencer TJ; Biederman J; Milton DR; Michelson D
    J Am Acad Child Adolesc Psychiatry; 2005 Mar; 44(3):240-8. PubMed ID: 15725968
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of atomoxetine for the treatment of ADHD symptoms in patients with pervasive developmental disorders: a prospective, open-label study.
    Fernández-Jaén A; Fernández-Mayoralas DM; Calleja-Pérez B; Muñoz-Jareño N; Campos Díaz Mdel R; López-Arribas S
    J Atten Disord; 2013 Aug; 17(6):497-505. PubMed ID: 22366240
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of atomoxetine for first-line treatment of newly diagnosed, treatment-naïve children and adolescents with attention deficit/hyperactivity disorder.
    Montoya A; Hervas A; Cardo E; Artigas J; Mardomingo MJ; Alda JA; Gastaminza X; García-Polavieja MJ; Gilaberte I; Escobar R
    Curr Med Res Opin; 2009 Nov; 25(11):2745-54. PubMed ID: 19785510
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential response profiles in children and adolescents with attention-deficit/hyperactivity disorder: treatment with atomoxetine.
    Wietecha LA; Wang S; Saylor KE; Day KA; Wu SH; Kelsey D
    Clin Pediatr (Phila); 2015 Feb; 54(2):164-73. PubMed ID: 25371450
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The treatment of attention deficit hyperactivity disorder with comorbid tic hyperkinesis].
    Chutko LS; Surushkina SIu; Nikishena IS; Iakovenko EA; Lapshina OV; Anisimova TI
    Zh Nevrol Psikhiatr Im S S Korsakova; 2008; 108(2):66-8. PubMed ID: 18646384
    [No Abstract]   [Full Text] [Related]  

  • 20. Atomoxetine for encopresis in 2 children with attention-deficit/hyperactivity disorder.
    Hergüner S; Hergüner A
    J Clin Psychopharmacol; 2012 Apr; 32(2):302-3. PubMed ID: 22388168
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.